Skip to main content
SpringerLink
Log in

Phase II study of mitoxantrone for liver metastases from breast cancer

  • Original Articles
  • Mitoxantrone, Liver Metastases, Breast Cancer
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Mitoxantrone was given to 19 patients with liver metastases from breast cancer and biochemical evidence of liver dysfunction. In all, 2 patients received the drug at a dose of 10 mg/m2 on days 1 and 2 of the first course of treatment; 1 patient was given 9 mg/m2 and 17 received 8 mg/m2. Subsequent courses were given at a dose of 10 mg/m2. Three patients (16%) showed a partial response, with time to progression of between 3 and 7 months. Toxicity was considerable, with myelosuppression being the major problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cheblowski RT, Tong M, Bulcavage L, Woodward D (1986) Mitoxantrone in hepatic dysfunction: factors influencing toxicity and response. Proc ASCO 5:178

    Google Scholar 

  2. Coleman RE, Rubens RD (1987) The clinical course of bone metastases in breast cancer. Br J Cancer 55:61–66

    Google Scholar 

  3. Coleman RE, Maisey MN, Knight RK, Rubens RD (1984) Mitoxantrone in advanced breast cancer: a phase II study with special attention to cardiotoxicity. Eur J Cancer Clin Oncol 20:771–774

    Google Scholar 

  4. Cornbleet MA, Stuart-Harris RC, Smith IE, Coleman RE, Rubens RD, McDonald M, Mourisden HT, Rainer H, Von Oosterom AT, Smyth JF (1984) Mitoxantrone for the treatment of advanced breast cancer. Eur J Clin Oncol 20:1141–1146

    Google Scholar 

  5. Hayward JL, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A, Rubens RD (1977) Assessment of response to therapy in advanced breast cancer. Eur J Cancer 13:89–94

    Google Scholar 

  6. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214

    Google Scholar 

  7. Perlow LS, Holland JF (1984) Chemotherapy of breast cancer. Med Oncol Tumour Pharmacother 1:169–192

    Google Scholar 

  8. Savaraj N, Lu K, Valdivieso M, Burgess M, Umsawasdi T, Benjamin RS, Loo TL (1982) Clinical kinetics of 1,4-dihydroxy-5,8-bis[(2-[2-hydroxyethyl)aminolethylamino]-9,10 anthracenedione. Clin Pharmacol Ther 3:312–316

    Google Scholar 

  9. Twelves CJ, Coleman RE, O'Reilly SM, Richards MA, Rubens RD (1988) Weekly epirubicin for liver metastases in breast cancer (Abstract). Br J Cancer 58:268

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. ICRF Clinical Oncology Unit, Guy's Hospital, SE1 9RT, London, U.K.

    S. M. O'Reilly, R. E. Coleman & R. D. Rubens

Authors
  1. S. M. O'Reilly
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. E. Coleman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. D. Rubens
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

O'Reilly, S.M., Coleman, R.E. & Rubens, R.D. Phase II study of mitoxantrone for liver metastases from breast cancer. Cancer Chemother. Pharmacol. 25, 73–74 (1989). https://doi.org/10.1007/BF00694343

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00694343

Keywords

Search

Navigation